AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01610674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored improvement strategy
Description: A step-wise implementation model is applied:~1) recommendations on optimal perioperative diabetes care (e.g. the administration of intravenous insulin, encouragement of diabetes self-management) are systematically translated into quality indicators; 2a) using these quality indicators, current care is measured by performing a medical record search among 400 patients in 6 hospitals; 2b) barriers and facilitators for optimal care are measured by performing interviews with professionals 3) based on this information an implementation strategy is developed; 4) implementation activities are enacted in 3 hospitals and 5) evaluated in a controlled before-after design in 6 hospitals providing before and after intervention 400 patients.
Study NCT02667704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Study NCT02667704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Study NCT03891433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem 1000 MG
Description: Carbapenems group intervention.
Study NCT03891433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin, Tazobactam 4-0.5G Solution for Injection
Description: Piperacillin/Tazobactam group intervention.
Study NCT01851122 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-theanine capsule
Description: L-theanine 250mg capsule
Study NCT01851122 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Study NCT02176655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VVD-101
Description: All subjects will treat 6 headaches with either VVD-101 or placebo in a randomized order.
Study NCT02176655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All subjects will treat 6 headaches with either VVD-101 or placebo in a randomized order.
Study NCT05009693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Light Application
Description: White Light Therapy
Study NCT04201574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALY688 0.1%
Description: ALY688 0.1% Ophthalmic Solution
Study NCT04201574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALY688 0.4%
Description: ALY688 0.4% Ophthalmic Solution
Study NCT04201574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Ophthalmic Solution
Study NCT00669097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258
Study NCT01316003 — intervention group
Intervention type: OTHER
Intervention: Optical coherence tomography
Description: Optical coherence tomography
Study NCT01708382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study NCT04620447 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intelligent Virtual Reality Therapy System (IVRTS)
Description: The approach of the Novel Intelligent Software interface approaches follows the basic premise that human beings think in terms of images rather than words. While the existing modes of treatment for phobias rely mainly on talk therapies and counseling; This novel intelligent software treatment methodology deals with the development of VR programs integrated with hardware for simulating various phobia-inducing situations, followed by novel automated integrated most effective psychotherapy; altering these images to reduce the anxiety experienced. Our treatment package includes a VR device integrated with easily comprehensible voice commands, along with a user manual and easy user interface, thereby reducing the effort of training required for operating the device. The framework is a combination of the therapy methodologies with VR, motion sensors and biofeedback.
Study NCT00751920 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enhanced MRI Scan
Description: Following the detection of a pulmonary nodule(s) with the unenhanced MRI scan, the subjects will then be injected with the contrast agent, Magnevist, and have a dynamic enhanced MRI scan of the largest pulmonary nodule.
Study NCT02089373 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy
Description: In this arm1, an investigator observes a cancerous lesion using white light endoscopy. In addition, contrast dye for confocal laser endomicorscopy (fluorescein sodium 0.1mL/kg) is administered. Then, the cancerous lesion is observed using probe-based confocal laser endomicroscopy. The biopsy would be done 5 times at the most suspcious parts of the cancerous lesion.
Study NCT02089373 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: White light endoscopy
Description: In this arm2, an invesigator observes a cancerous lesion using white light endoscopy. The biopsy would be done 5 times at the most suspicious parts of the cancerous lesion.
Study NCT00516022 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mistletoe extract
Description: The drug will be administered 3 times a week at home.
Study NCT00516022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mistletoe extract
Description: The drug will be administered 3 times a week at home.
Study NCT05056207 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cohort I (patients receiving annual lymphedema screening
Description: patientns who previously underwent preoperative perometer lymphedema screening
Study NCT05056207 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cohort II (patients followed intensively for lymphedema)
Description: patients who have recently undergone ALND
Study NCT00604591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tolcapone
Description: 200 mg by mouth three times a day
Study NCT00604591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone
Description: 200 mg by mouth three times a day
Study NCT00604591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 mg by mouth three times a day
Study NCT00604591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 200 mg by mouth three times a day
Study NCT00298272 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IDEC-C2B8 (rituximab)
Description: Participants will receive 500 mg rituximab on Day 1 and Day 15
Study NCT00298272 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Participants will receive placebo on Day 1 and Day 15
Study NCT00298272 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Description: Participants must have been treated with MTX ≥15 mg per week and ≤25 mg per week (dose may have been as low as 10 mg if unable to tolerate higher dose) for at least 12 weeks immediately prior to Day 1, at a stable dose for at least 4 weeks and was continued for the study duration.
Study NCT00298272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participants must have been treated with MTX ≥15 mg per week and ≤25 mg per week (dose may have been as low as 10 mg if unable to tolerate higher dose) for at least 12 weeks immediately prior to Day 1, at a stable dose for at least 4 weeks and was continued for the study duration.
Study NCT00298272 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Etanercept
Description: Participants must have been treated with etanercept at 50 mg per week (25 mg twice per week or 50 mg once per week).
Study NCT00298272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Participants must have been treated with etanercept at 50 mg per week (25 mg twice per week or 50 mg once per week).
Study NCT00298272 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Adalimumab
Description: Participants must have been treated with adalimumab at 40 mg every other week for at least 12 weeks immediately prior to Day 1.
Study NCT00298272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Participants must have been treated with adalimumab at 40 mg every other week for at least 12 weeks immediately prior to Day 1.
Study NCT00298272 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methylprednisolone
Description: Methylprednisolone 100 mg IV was administered by slow infusion to be completed at least 30 minutes prior to each infusion of rituximab or placebo.
Study NCT00298272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 100 mg IV was administered by slow infusion to be completed at least 30 minutes prior to each infusion of rituximab or placebo.
Study NCT00298272 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Folate
Description: All subjects also received a stable dose of folate (≥5 mg per week).
Study NCT00298272 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folate
Description: All subjects also received a stable dose of folate (≥5 mg per week).
Study NCT01216241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daptomycin
Description: 8 MG/KG IV
Study NCT01216241 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: 50 ml normal saline once daily
Study NCT01216241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daptomycin
Description: 8 mg/kg once daily
Study NCT01075165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: silicone spray
Description: application of silicone spray to predefined area qd 12 weeks
Study NCT01075165 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline spray
Description: application of saline spray to predefined area qd 12 weeks
Study NCT01209520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
Study NCT01209520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
Study NCT01209520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
Study NCT01209520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vidaza
Description: Patient will receive 5-azacitidine at a dose of 75 mg/m2 intravenously daily on day 1-5 every 28 days for 6 cycles
Study NCT01209520 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Specimen for Methylation Analysis
Description: Obtained from tissue of resected NSCLC tumor.
Study NCT01209520 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Sample for Methylation Analysis
Description: Pre-Surgery, Post-Surgery, Post-Vidaza Therapy and during follow-up.
Study NCT01209520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
Study NCT01209520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
Study NCT01209520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
Study NCT03550313 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Multivalent
Description: Pneumococcal conjugate vaccine
Study NCT03550313 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13
Description: Pneumococcal conjugate vaccine
Study NCT03550313 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13
Description: Pneumococcal conjugate vaccine
Study NCT02936557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987521
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z09-054)
Study NCT01297062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: IV Exenatide (therapeutic and supratherapeutic concentrations)
Study NCT01297062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Oral Moxifloxacin (400 mg)
Study NCT01297062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: IV Placebo (matching volume of placebo)
Study NCT03846700 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: aquablation
Description: minimally invasive, robot-assisted and ultrasound-guided ablation of the prostate in targeted way and in heat-free way working by high pression water jet
Study NCT03846700 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: holep
Description: holmium laser enucleation of prostate
Study NCT03846700 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pvp
Description: photoselectivevaporization of prostate
Study NCT00160433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 0.5 mg Tablet, oral Daily for 12 weeks
Study NCT00160433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 1.5 mg Tablet, oral Daily for 12 weeks
Study NCT00160433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 5.0 mg Tablet, oral Daily for 12 weeks
Study NCT00160433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, oral Daily for 12 weeks
Study NCT00622167 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Integrated Backscatter IVUS
Description: All subjects have Integrated Backscatter IVUS and Dual Source CT imaging.
Study NCT00622167 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dual Source Computed Tomography
Description: All subjects have DSCT and IBIVUS imaging
Study NCT03463902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: left IFG anodal
Description: Single session of transcranial direct current stimulation (tDCS) over left IFG anodal stimulation~2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
Study NCT03463902 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: left IFG cathodal
Description: Single session of transcranial direct current stimulation (tDCS) over left IFG cathodal stimulation~2 mA Stimulation of 10 min, cathodal electrode over left IFG, anodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
Study NCT03463902 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: left IPL anodal
Description: Single session of transcranial direct current stimulation (tDCS) over left IPL anodal stimulation 2 mA Stimulation of 10 min, anodal electrode over left IPL, cathodal electrode over right IPL, 30 sec ramp to start and 30 sec ramp to stop
Study NCT03463902 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: left IPL cathodal
Description: Single session of transcranial direct current stimulation (tDCS) over left IPL cathodal stimulation 2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
Study NCT03463902 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single session of placebo tDCS over left IFG 10 min duration, 30 sec ramp during start and end
Study NCT02818881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-speed yoga
Study NCT02818881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-speed yoga
Study NCT03034148 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Platelet Acetyl Coenzyme A Carboxylase analysis in CAD
Study NCT02676869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP321 (eftilagimod alpha)
Description: Part A: Single subcutaneous injections of 1 mg (cohort 1), 6 mg (cohort 2) or 30 mg (cohort 3) of IMP321 administered every 2 weeks~Part B: Single subcutaneous injections of 30 mg of IMP321 administered every 2 weeks
Study NCT02676869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered according to the approved label.
Study NCT03336619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Nitazoxanide 600 mg administered orally twice daily for five days
Study NCT03336619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally twice daily for five days
Study NCT01446458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFIRINOX
Description: Patients receive modified FOLFIRINOX Chemotherapy for 4 cycles (1 cycle = 15 days). Modified FOLFIRINOX: Oxaliplatin 85 mg/m2 intravenous infusion on day 1; Irinotecan 180 mg/m2 intravenous infusion on day 1; 5-Fluorouracil 2400 mg/m2 continuous intravenous infusion on days 1 to 3; pegylated filgrastim (neulasta) 6 mg subcutaneous injection on day 3.
Study NCT01446458 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: Patients will receive Stereotactic Body Radiotherapy (SBRT) to pancreas tumor 2 weeks following chemotherapy. SBRT is given in 3 daily fractions at designated doses per treatment cohort. Starting dose level-Dose level 1: 10 Gy SBRT to primary tumor volume (PTV) / 2 Gy SBRT to the retroperitoneal margin daily for a total Gy to Gross tumor volume (GTV) of 36 Gy. There are weekly toxicity assessments for 4 weeks. This is a standard 3 + 3 design with 4 dose levels.
Study NCT02370706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: CDK4/6 inhibitor
Study NCT03555370 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vestibular Exercise Intervention
Description: The vestibular exercise intervention group will complete behavioral management activities, and prescribed in--office/at home vestibular exercises from four groups: 1) gaze stability training (integrated eye and head movements on fixed target), 2) visual motion training (integrated eye and head movements on moving target), 3) standing balance (standing with eyes closed in different stances), and 4) dynamic gait (walking with head turns and eye movements). Participants will be prescribed to one of four levels of these exercise groups based on presentation of symptoms/impairment as indicated on VOMS. Progression through the levels will be based on symptom tolerance and successful completion of all exercises at the current level.
Study NCT03555370 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: The standard of care consists of standardized in office/at home behavioral management including sleep, hydration, nutrition, and stress management interventions.
Study NCT04843085 — intervention group
Intervention type: OTHER
Intervention: Proteomic analysis
Description: : Proteomic analysis in the 3 subgroups of oligodendrogliomas (O1, O2 and O3) and in the comparator groups of IDH-mutant astrocytomas, IDH-wildtype glioblastomas and normal brain samples
Study NCT05773690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Movement quality
Description: 6-week-home-based training protocols designed to improve general fitness levels and postural control performed in a circuit-training mode (time of work per set 30 s, time of rest between each exercise 15 s, time of rest between sets 2 min, total volume 3 sets) for a duration of 45 min with a frequency of 3 days per week while performing mobility, stability and motor control exercises.
Study NCT05773690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Resistance Training
Description: 6-week-home-based training protocols designed to improve general fitness levels and postural control performed in a circuit-training mode (time of work per set 30 s, time of rest between each exercise 15 s, time of rest between sets 2 min, total volume 3 sets) for a duration of 45 min with a frequency of 3 days per week while performing traditional strength training exercises
Study NCT02625766 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LC fracture surgical fixation
Study NCT02625766 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LC fracture non-operative management